期刊文献+

先天性心脏病合并肺动脉高压低体质量患儿血浆偶联因子6的含量及意义 被引量:4

CHANGES OF COUPLING FACTOR 6 FOR CONGENITAL HEART DISEASE AND PULMONARY HYPERTENSION IN LOW MASS CHILDREN
下载PDF
导出
摘要 目的研究先天性心脏病合并不同程度肺动脉高压患儿血浆中偶联因子6(coupling factor 6,CF6)含量的变化,以探讨CF6在本疾病中的作用。方法收集2011年1月—2012年8月160例先天性心脏病合并不同程度肺动脉高压患儿。随机分为3组,先天性心脏病未合并肺动脉高压组41例为对照组,先天性心脏病合并肺动脉高压但未达到重度肺动脉高压组76例为A组,先天性心脏病合并重度肺动脉高压组43例为B组。应用放射免疫分析法检测不同组别血浆中CF6的含量。结果对照组CF6含量(199.5±44.7)ng/L,A组(168.7±99.8)ng/L,B组(305.4±81.7)ng/L。对照组与A组之间CF6含量差异无统计学意义(P>0.05),B组CF6含量较对照组、A组明显升高(P<0.01)。结论先天性心脏病合并重度肺动脉高压的低体质量患儿血浆中CF6含量明显升高,提示CF6可能在其病理生理过程中发挥重要的作用。 Objective To explore the changes of coupling factor 6 in plasma for congenital heart disease(CHD) complicated with different degrees of pulmonary hypertension in low mass children. Methods A total of 160 patients with CHD complicated with different degrees of pulmonary hypertension from January 2011 to August 2012 were retrospectively analyzed. The 160 cases were divided into three groups: CHD without pulmonary artery hypertension as control group, CHD with pulmonary artery hypertension but not the highest as A group, CHD with the highest pulmonary artery hypertension as B group. The plasma CF6 level was determined by radio immunoassay for three groups. Results CF6 level in control group was ( 199.5 ± 44.7) ng/L, A group ( 168.7 ± 99.8 ) ng/L, B group ( 305.4 ± 81.7 ) ng/L. Control group and A group had no significant difference( P 〉0.05 ). CF6 level in B group was obviously higher compared with that of A group and control group, the difference had statistical significance (P 〈 0. O1 ). Conclusion The plasma CF6 level is obviously increased in CHD with the highest pulmonary artery hypertension. CF6 may play an important role in the pathogenesis of the disease.
出处 《河北医科大学学报》 CAS 2013年第12期1501-1503,共3页 Journal of Hebei Medical University
关键词 先天性心脏病 肺动脉高压 偶联因子 congenital heart disease pulmonary hypertension coupling factor
  • 相关文献

参考文献7

二级参考文献43

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量:1796
  • 4Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery : a randomised doubleblind study. Lancet, 2000,3.56:1464- 1469.
  • 5Schranz D, Zepp F, Iversen S, et al. Effects of tolazoline and prostacyclin in pulmonary hypertension in infants. Crit Care Med, 1992, 20:1243- 1249.
  • 6Bando K, Turrentine MW, Sharp TG et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management.J Thorac Cardiovasc Surg, 1996, 112: 1600- 1607.
  • 7周永昌 郭万学.超声医学[M].北京:科学技术文献出版社,1998.1055-1059.
  • 8Proceeding of 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol, 2004,43(2 Suppl S) : 1S-90S.
  • 9Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126( Suppl 1 ) : 1 S-92S.
  • 10Galie N, Torbicki A, Barst A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004,25 ( 24 ) : 2243-2278.

共引文献330

同被引文献32

  • 1白亚莲,魏亚娟,乞艳华,刘保民.超声心动图产前诊断胎儿先天性心脏病的临床价值[J].西安交通大学学报(医学版),2011,32(6):768-771. 被引量:30
  • 2无.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35(11):979-987. 被引量:275
  • 3Schuuring M, Bouma B. Treatment of segmental pulmonary artery hyper- tension in adults with congenital heart disease[ J]. Int J Cardiol,2013, 164 ( 1 ) : 106 - 110. DOI : 10.1016/j. ijcard. 2011.06. 084.
  • 4Osanai T, Tanaka M, Magota K, et al. Coupling factor 6-induced activa- tion of ecto-F1 Fo complex induces insulin resistance, mild glucose into- lerance and elevated blood pressure in mice [ J ]. Diabetologia, 2012,55 (2) :520 - 529. DOI : 10. 1007/s00125-011-2341 -z.
  • 5Sharma V, Berkelhamer S, Lakshminrusimha S. Persistent pulmonary hy- pertension of the newborn [ J]. Mate Heal Neon Perinatol, 2015,155 (2) :20 -29. DOI:10.1186/s40748-015-0015-4.
  • 6Osanai T, Magota K, Okumura K. Coupling factor 6 as a novel vasoactive and proatherogenic peptide in vascular endothelial cells. [J].Naunyn Schmiedebergs Arch Pharmacol, 2009,380 ( 3 ) : 205 - 214. DOI : 10. 1007/s00210-009-0431 -y.
  • 7Predescu D, Chaturvedi RR, Friederg MK, et al. Complete heart block associated with device closure of perimembranous ventricular septal defects [J]. J Thorae Cardiova~c Surg, 2008,136(5) : 1223-- 1228.
  • 8Traineau R, Elghouzzi MH, Bierling P. Update on infectious risks associated with blood products[J]. Rev Prat, 2009,59 (1) :86--89.
  • 9Strainer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety[J]. Transfusion, 2009,49 (Suppl 2) : 1S-- 29S.
  • 10刘小清,麦劲壮,庄建.先天性心脏病流行病学研究方法新认识[J].中国循环杂志,2011,26(1):74-76. 被引量:19

引证文献4

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部